P072: Use of tadalafil in MEGDEL syndrome

Documenti analoghi

• Are viral vector-mediated therapies compatible with aberrant glycosylation?
  di: I.J.J. Muffels, et al.
  Pubblicazione: (2025-09-01)
• P032: Improving ataxia symptoms in patients with monoallelic DHDDS-CDG using nicotinamide precursor supplements
  di: Drew Sinha, et al.
  Pubblicazione: (2025-01-01)
• P072: Use of tadalafil in MEGDEL syndrome
  di: Daniel Schecter, et al.
  Pubblicazione: (2025-01-01)
• Normal transferrin glycosylation does not rule out severe ALG1 deficiency
  di: Inez Bosnyak, et al.
  Pubblicazione: (2024-05-01)
• O05: Fractionated plasma N-glycan analysis identifies sensitive diagnostic biomarkers for congenital disorders of glycosylation (CDG)
  di: Earnest James Paul Daniel, et al.
  Pubblicazione: (2023-01-01)